Results 171 to 180 of about 14,191 (208)
Some of the next articles are maybe not open access.
Clinical Trials with Pseudomonas Exotoxin Immunotoxins
1998Pseudomonas exotoxin (PE) has been used to make immunotoxins for cancer therapy for more than a decade (FitzGerald et al. 1983). The function of PE is described in detail elsewhere in this book. In summary, PE is a 613 amino acid (66kDa) single-chain protein secreted by Pseudomonas aeruginosa. X-ray crystallography (Allured et al.
L H, Pai, I, Pastan
openaire +2 more sources
The Role of Exotoxin A in Pseudomonas Disease and Immunity
Clinical Infectious Diseases, 1983Exotoxin A is an extracellular enzyme that is produced by most clinical strains of Pseudomonas aeruginosa. It is a single-chain polypeptide (molecular weight, 71,000) with A and B fragments that mediate enzymatic and cell-binding functions, respectively.
openaire +2 more sources
Redirecting Pseudomonas exotoxin.
Seminars in cell biology, 1992Pseudomonas exotoxin (PE) is a three-domain bacterial toxin that kills mammalian cells by gaining entry to the cytosol and inactivating protein synthesis. The pathway of toxin entry includes binding to a surface receptor, internalization via coated pits and endosomes, proteolytic processing, reduction of disulfide bonds and finally the translocation of
D, FitzGerald, I, Pastan
openaire +1 more source
[21] Preparation of Pseudomonas exotoxin A
1988Publisher Summary This chapter describes the preparation of Pseudornonas exotoxin A (PE). PE is one of the major virulence factors of Pseudomonas aeruginosa . A low protease-producing strain PAl03 is usually used for exotoxin production. The undefined growth medium for PE production is the dialysate of trypticase soy broth (TSB).
Kenneth J Kozak, Catharine B Saelinger
openaire +1 more source
Pseudomonas aeruginosa exotoxin A
1997Abstract Pseudomonas aeruginosa exotoxin A (PEA, MW 66 kDa, 613 amino acids, sequence accession number: PSEETA K01397) consists of three major domains (Allured et al. 1986), as indicated in Fig. 1. The N-terminal domain la (amino acids 1-252) binds to the ai-macroglobulin receptor at the cell surface (Kounnas et al.
openaire +1 more source
Resistance of Exotoxin A to Purified Pseudomonas Proteolytic Enzymes
Infection and Immunity, 1980Pseudomonas toxin is produced as a proenzyme which is cytotoxic for cells in culture but must be activated to express full enzymatic activity. The ability of purified pseudomonas alkaline protease and elastase or of culture filtrates of two strains of Pseudomonas aeruginosa to modify the activity of pseudomonas ...
K, Jagger, M M, Nickol, C B, Saelinger
openaire +2 more sources
The acid-triggered entry pathway of Pseudomonas exotoxin A
Biochemistry, 1989In this study we examined the pH requirements and reversibility of early events in the Pseudomonas toxin entry pathway, namely, membrane binding, insertion, and translocation. At pH 7.4, toxin binding to vesicles and insertion into the bilayer are very inefficient. Decreasing the pH greatly increases the efficiencies of these processes.
Z T, Farahbakhsh, B J, Wisnieski
openaire +2 more sources
Cancer research, 1991
Immunotoxins are potent cell-killing agents that may be useful in the treatment of cancer. The early production of neutralizing antibodies to immunotoxins is one of the major limiting factors for their use in humans. 15-Deoxyspergualin (DSG), a derivative of spergualin, which is a metabolite of Bacillus laterosporus, has been found to have ...
L H, Pai +5 more
openaire +1 more source
Immunotoxins are potent cell-killing agents that may be useful in the treatment of cancer. The early production of neutralizing antibodies to immunotoxins is one of the major limiting factors for their use in humans. 15-Deoxyspergualin (DSG), a derivative of spergualin, which is a metabolite of Bacillus laterosporus, has been found to have ...
L H, Pai +5 more
openaire +1 more source
Immunotoxins containing Pseudomonas exotoxin A: a short history
Cancer Immunology, Immunotherapy, 2003A large variety of monoclonal antibodies (MAb) have been identified that bind to antigens on cancer cells and there are many mechanisms by which antibodies can kill cancer cells. However, very few antibodies are able to kill sufficient numbers of cells to cause tumor regression in experimental animals and even fewer are useful in the treatment of ...
openaire +2 more sources